Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03088540 · OUTCOME

Number of Participants With Laboratory Abnormalities

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to approximately 28 months

What was measured

Reported here is the number of participants with at least one laboratory abnormality of any grade in measurements for hematology, electrolytes, liver function, chemistry, and coagulation.

Analysis population: SAF included all randomized participants who received any study drug. "Overall number of participants analyzed" includes all participants evaluable for this outcome measure, and "number analyzed" is the number of participants with at least one post-baseline value for that parameter.

Groups in this outcome

Cemiplimab

Participants received cemiplimab monotherapy

Chemotherapy

Participants received platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cemiplimab356
Chemotherapy343

Reported measurements

Hematology

Analysis denominator · Participants

GroupSource count
Cemiplimab344
Chemotherapy332
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab230Not reportedNot reportedNot reportedNot reported
Chemotherapy301Not reportedNot reportedNot reportedNot reported
Electrolytes

Analysis denominator · Participants

GroupSource count
Cemiplimab343
Chemotherapy328
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab278Not reportedNot reportedNot reportedNot reported
Chemotherapy253Not reportedNot reportedNot reportedNot reported
Liver Function

Analysis denominator · Participants

GroupSource count
Cemiplimab343
Chemotherapy328
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab255Not reportedNot reportedNot reportedNot reported
Chemotherapy195Not reportedNot reportedNot reportedNot reported
Chemistry

Analysis denominator · Participants

GroupSource count
Cemiplimab343
Chemotherapy328
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab296Not reportedNot reportedNot reportedNot reported
Chemotherapy258Not reportedNot reportedNot reportedNot reported
Coagulation

Analysis denominator · Participants

GroupSource count
Cemiplimab190
Chemotherapy155
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab40Not reportedNot reportedNot reportedNot reported
Chemotherapy21Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        230
      2. group Id
        OG001
        value
        301
    denoms
    1. counts
      1. group Id
        OG000
        value
        344
      2. group Id
        OG001
        value
        332
      units
      Participants
    title
    Hematology
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        278
      2. group Id
        OG001
        value
        253
    denoms
    1. counts
      1. group Id
        OG000
        value
        343
      2. group Id
        OG001
        value
        328
      units
      Participants
    title
    Electrolytes
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        255
      2. group Id
        OG001
        value
        195
    denoms
    1. counts
      1. group Id
        OG000
        value
        343
      2. group Id
        OG001
        value
        328
      units
      Participants
    title
    Liver Function
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        296
      2. group Id
        OG001
        value
        258
    denoms
    1. counts
      1. group Id
        OG000
        value
        343
      2. group Id
        OG001
        value
        328
      units
      Participants
    title
    Chemistry
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        40
      2. group Id
        OG001
        value
        21
    denoms
    1. counts
      1. group Id
        OG000
        value
        190
      2. group Id
        OG001
        value
        155
      units
      Participants
    title
    Coagulation
denoms
  1. counts
    1. group Id
      OG000
      value
      356
    2. group Id
      OG001
      value
      343
    units
    Participants
description
Reported here is the number of participants with at least one laboratory abnormality of any grade in measurements for hematology, electrolytes, liver function, chemistry, and coagulation.
groups
  1. description
    Participants received cemiplimab monotherapy
    id
    OG000
    title
    Cemiplimab
  2. description
    Participants received platinum-based doublet chemotherapy
    id
    OG001
    title
    Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
SAF included all randomized participants who received any study drug. "Overall number of participants analyzed" includes all participants evaluable for this outcome measure, and "number analyzed" is the number of participants with at least one post-baseline value for that parameter.
reporting Status
POSTED
time Frame
Up to approximately 28 months
title
Number of Participants With Laboratory Abnormalities
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice